Silo Pharma Reports Positive Data For SP-26 Ketamine Implant In Preclinical Study

Silo Pharma, a biopharmaceutical firm, announced optimistic preclinical data from its ongoing research of SP-26, which is a long-lasting implantable ketamine formulation meant to treat patients dealing with chronic pain and fibromyalgia. The SP-26 implant functions as a patient-administered non-opioid drug that promises lasting pain relief without exposing users to traditional pain medication dangers. The non-GLP study initiated in December 2024 represents the first time SP-26 underwent testing within small animals for preclinical development. 

“We are encouraged by the early initial data from the SP-26 animal study, with no abnormal clinical observations reported. We believe that a successful outcome would provide clear, actionable data for validating the advancing of SP-26 as a potential treatment for chronic pain,” said Eric Weisblum, CEO of Silo. 

The implantation procedure (dosing) took place in early January 2025, and all animals remained free from significant adverse effects that would indicate unsafe behaviour. Research investigators are completing the testing on absorption, distribution, metabolism, and excretion (ADME) functions in the present study period. The final safety alongside pharmacokinetic reports about SP-26 will become available in March 2025, revealing essential details regarding its potential as an innovative pain management medicine.